![The F-35’s future: The power and cooling competition that could change everything [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/09/240924_F35_moon_USAF-scaled-e1727200160419.jpg?#)
Candel sheds more light on successful late-stage trial of prostate cancer immunotherapy
In December, the share price of Candel Therapeutics surged by more than 200% when the company revealed the success of a phase 3 trial of CAN-2409 in localized prostate cancer. Five months later, Candel has unveiled more information from the study, bolstering the value of the first-in-class treatment.
In December, the share price of Candel Therapeutics surged by more than 200% when the company revealed the success of a phase 3 trial of CAN-2409 in localized prostate cancer. Five months later, Candel has unveiled more information from the study, bolstering the value of the first-in-class treatment.
